Federal drug labels now say some popular diabetes pills have triggered fatal cases of a rare but dangerous condition called ketoacidosis.
Story Snapshot
- The Food and Drug Administration (FDA) added class-wide warnings for sodium-glucose cotransporter-2 inhibitors about ketoacidosis.
- Official labels for empagliflozin (Jardiance) and dapagliflozin (Farxiga) report fatal ketoacidosis cases.
- Labels warn ketoacidosis can occur even if blood sugar is under 250 mg/dL, so symptoms matter more than a single reading.
- Patients are told to stop the drug and seek urgent care if symptoms point to ketoacidosis.
What the FDA Put in Writing and Why It Matters
The Food and Drug Administration warned in 2015 that all drugs in this class carry a risk of too much acid in the blood, known as ketoacidosis. The agency ordered new label language for the entire group. That means the warning applies to the drugs as a class, not just one brand. The Food and Drug Administration alert flagged symptoms and urged quick medical care if they appear, because delay can turn dangerous fast.
Peer-reviewed medical literature soon echoed the class-wide scope. Review authors stated that all drugs in this group now carry a ketoacidosis warning. That matched the Food and Drug Administration’s action and helped doctors align practice with the label. The shared message: watch for symptoms, and act early. A label warning does not mean common, but it does mean serious if missed.
What the Labels Say for Named Drugs
The label for empagliflozin, sold as Jardiance, calls ketoacidosis a life-threatening condition that needs urgent hospital care. It adds that fatal cases have been reported in patients who took the drug. The label also tells clinicians to check for ketoacidosis even when blood sugar is not very high, because it can occur with levels below 250 mg/dL. That is the “euglycemic” form that hides in plain sight.
Dapagliflozin, sold as Farxiga, carries the same core warning. Its label states that fatal cases of ketoacidosis have been reported. It tells patients to stop the pill and get medical help right away if they feel symptoms that fit ketoacidosis. That direct instruction matters, because waiting at home can cost precious hours. The most current label also underscores higher risk in certain settings and in insulin-deficient states.
Who Faces the Highest Risk and When Trouble Strikes
Trials and clinical experience show higher danger in people with type 1 diabetes, where insulin lack is central. The dapagliflozin label states that adding the drug in type 1 diabetes raised the rate of diabetic ketoacidosis above the background level in placebo groups. Certain stressors stack the deck: surgery, illness, fasting, dehydration, heavy alcohol intake, or missed insulin. Those conditions nudge the body toward ketone build-up, and the drug can tip the balance.
Symptoms should trigger action, not a debate. The labels and the Food and Drug Administration notice point to nausea, vomiting, belly pain, trouble breathing, unusual tiredness, and confusion. A normal or only modestly high glucose reading does not rule out danger. The safe move is to stop the drug and get urgent care for rapid blood and ketone testing. Doctors can then give fluids, insulin, and electrolytes to reverse the acid load.
How to Use These Drugs Safely Without Fear
These medicines help many patients. They lower blood sugar, shed fluid, and support heart and kidney health for some. None of that cancels the rare but real ketoacidosis risk. The conservative path fits common sense: know the red flags, pause the drug before surgery or long fasts per doctor advice, drink fluids, and never skip insulin if you need it. That is not alarmism. That is adult risk control grounded in the label and basic prudence.
Doctors should brief patients before the first pill. A one-minute script works: if you get sick, cannot eat, or feel these symptoms, stop the drug and call or go to urgent care now. Ask for ketone testing even if glucose looks fine. That script reflects the Food and Drug Administration’s instruction and the manufacturer’s own words. It protects patients without scaring them away from a drug that may help them reach their goals.
Sources:
mirror.co.uk, pmc.ncbi.nlm.nih.gov, accessdata.fda.gov, fda.gov, scirp.org, jamanetwork.com
